Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS


A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis




The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal stem cell transplantation, involving approximately 24 ambulatory participants with relapsing forms of MS (approximately equal numbers with relapsing-remitting and secondary progressive/ progressive relapsing MS) and evidence of involvement of the anterior afferent visual system.

Study Status: Active, not recruiting


Condition Intervention Phase
Relapsing-Remitting Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Progressive Relapsing Multiple Sclerosis
Biological: Autologous mesenchymal stem cell transplantation Phase 1

Verified by The Cleveland Clinic November, 2013

Sponsored by: The Cleveland Clinic
Information provided by: The Cleveland Clinic identifier: NCT00813969

Study Type: Interventional

Study Design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Mellen Center
Cleveland, Ohio 44195
United States

Jeffrey A Cohen, M.D.., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site